This system disrupts the Dectin-1-galectin-9 signaling axis in PDAC by reversing the immune-suppressive phenotype of TAMs, increasing the proportion of effector T cells in the tumor, and reducing Tregs, thereby inhibiting tumor progression [27]. Here, CLEC7A is linked to neoplasm.